A Study to Evaluate the Effects of Renal Function on Pharmacokinetics and Safety of DA-8010

NCT05812417 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-06-26

No results posted yet for this study

Summary

This Study will evaluate the effects of renal function on pharmacokinetics and safety of DA-8010

Conditions

  • Renal Impairment
  • Healthy

Interventions

DRUG

DA-8010

DA-8010 5mg single dose administration

Sponsors & Collaborators

  • Dong-A ST Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2024-06-07
Completion
2024-06-07

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05812417 on ClinicalTrials.gov